Article

VIDEO: Thomas Stinchcombe, MD, Discusses the Treatment of Non-Small Cell Lung Cancer

Conference|NAMCP: National Association of Managed Care Physicians Forum

Thomas Stinchcombe, MD, assistant professor of clinical research, UNC Lineberg Comprehensive Cancer Center, discusses the treatment of patients with non-small cell lung cancer (NSCLC).

Thomas Stinchcombe, MD, assistant professor of clinical research, UNC Lineberg Comprehensive Cancer Center, discusses the treatment of patients with non-small cell lung cancer (NSCLC). In order to manage cost, Dr Stinchcombe says that molecular testing allows clinicians to pick the correct treatment for the patient.

This video was taken on November 8 at the NAMCP Fall Managed Care Forum in Las Vegas, NV.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Dr John Mascarenhas
Dr Pankit Vachhani
Dr John Mascarenhas
Dr John Mascarenhas
Dr Xavier Leleu
Dr Xavier Leleu
Related Content
Joshua K. Sabari, MD | Image: NYU Langone
Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey
Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Doctor looking at lung imaging | Image credit: shidlovski – stock.adobe.com
June 26th 2025

Deep Learning Biomarkers Help Uncover ENV-101 Treatment Effects in IPF

Hayden E. Klein
At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com
June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan
Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.
Richard J. Nowak, MD, MS | Image Credit: Yale School of Medicine
June 24th 2025

Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS

Maggie L. Shaw Richard J. Nowak, MD, MS
In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo